Nutex Health Inc.

NasdaqCM:NUTX 株式レポート

時価総額：US$1.5b

Nutex Health 将来の成長

Future 基準チェック /16

Nutex Healthは、6.7%と8.1%でそれぞれ年率6.7%で利益と収益が成長すると予測される一方、EPSはgrowで0.7%年率。

主要情報

6.7%

収益成長率

0.71%

EPS成長率

Healthcare 収益成長17.4%
収益成長率8.1%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日04 Sep 2026

今後の成長に関する最新情報

分析記事 • Aug 12

Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target

The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...

Recent updates

ナラティブ更新 • Sep 08

NUTX: Arbitration Model And Micro Hospitals Will Drive Future Upside

Nutex Health’s updated analyst price target has moved from $290 to $325, with analysts pointing to the company’s micro-hospital footprint, arbitration-driven model, and capital-light expansion approach as key support for the higher fair value estimate. Analyst Commentary Recent research on Nutex Health focuses on how its micro-hospital network, arbitration-driven revenue model, and capital-light expansion plans feed into the updated valuation views.
ナラティブ更新 • Aug 25

NUTX: Arbitration Reset And Capital-Light Expansion Will Shape Future Upside

Analysts have raised their Nutex Health fair value estimate to $200 from $175, reflecting updated assumptions that factor in recent price target increases on the stock, a shift in projected revenue growth and profitability, and changes in expected future P/E levels. Analyst Commentary on Nutex Health Recent Street research on Nutex Health points to a mix of optimism around the company’s business model and questions about the quality and sustainability of some profit drivers.
Seeking Alpha • Aug 12

Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade)

Summary Nutex Health upgraded to "Strong Buy" as margin expansion and patient volume growth drive bullish outlook. Despite a 13% YoY revenue decline, Q2 saw 9.6% patient volume growth and significant, sustainable operating cost reductions. CMS administrative fee cuts and the HaloMD contract amendment are expected to lower normalized costs by 25%–30% in future periods. With a 6.6x GAAP TTM PE, upside catalysts include the No Surprises Enforcement Act and $356 million in accounts receivable potentially converting to cash. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 10

NUTX: Arbitration Model And Margin Gains Will Support Future Upside

Nutex Health's analyst price target has shifted from $235.50 to $266.40. Analysts point to fresh coverage highlighting its micro hospital model, arbitration driven reimbursement approach, and capital light expansion plans as key factors in their updated views.
ナラティブ更新 • Jun 22

NUTX: Low EV EBITDA Multiple And Buyback Activity Will Support Future Upside

Analysts nudged their Nutex Health price target to $235, pointing to what they view as a low ~3x EV/EBITDA multiple, limited existing coverage, and ongoing investor confusion around the No Surprises Act as key factors behind their valuation work. What’s in the News for Nutex Health Nutex Health reported completing a share repurchase tranche between March 5, 2026 and March 31, 2026, buying 21,086 shares, or 0.3% of outstanding shares, for a total of US$3.02 million under the buyback announced on March 5, 2026.
ナラティブ更新 • Jun 04

NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential

Analysts have raised their Nutex Health fair value estimate from $221.67 to $235.50, citing what they describe as a relatively low ~3x EV/EBITDA multiple and limited prior coverage of the stock as key reasons for the higher $235 price target. What's in the News No recent company specific news, periodical coverage, or key developments were identified in the provided sources for Nutex Health.
ナラティブ更新 • May 09

NUTX: Share Repurchases Will Support Future Margins And Upside Potential

Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.
ナラティブ更新 • Apr 23

NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside

Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.
ナラティブ更新 • Apr 09

NUTX: New Buyback Program Will Support Future Margin Resilience

Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).
ナラティブ更新 • Mar 25

NUTX: Share Repurchases Will Support Future Upside Potential

Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).
ナラティブ更新 • Mar 11

NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience

Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.
ナラティブ更新 • Feb 25

NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience

Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).
ナラティブ更新 • Feb 11

NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay

Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.
ナラティブ更新 • Jan 27

NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk

Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).
ナラティブ更新 • Jan 12

NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds

Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.
ナラティブ更新 • Dec 26

NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations

Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.
ナラティブ更新 • Dec 12

NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations

Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).
User avatar
新しいナラティブ • May 28

Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges

Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.
分析記事 • Jan 24

Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Dec 25

Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks

When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...
分析記事 • Aug 12

Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target

The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...
分析記事 • Apr 17

Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues

Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...
Seeking Alpha • Aug 23

Nutex Health GAAP EPS of -$0.03, revenue of $58.05M

Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.

業績と収益の成長予測

NasdaqCM:NUTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20281,014206N/AN/A1
12/31/2027964208N/AN/A5
12/31/2026872198N/AN/A5
6/30/2026847180272280N/A
3/31/202688096265273N/A
12/31/202587571241248N/A
9/30/2025981121174178N/A
6/30/2025792568185N/A
3/31/2025624746971N/A
12/31/2024480522123N/A
9/30/2024292-412021N/A
6/30/2024276-381317N/A
3/31/2024259-41-33N/A
12/31/2023248-46-81N/A
9/30/2023232-2958N/A
6/30/2023197-436-7-2N/A
3/31/2023196-451616N/A
12/31/2022219-4253651N/A
9/30/2022229-3965893N/A
6/30/20223197092124N/A
3/31/2022336122123158N/A
12/31/2021332133137173N/A
9/30/202137415994160N/A
12/31/20202741062587N/A
12/31/20199721N/A12N/A

アナリストによる今後の成長予測

収入対貯蓄率: NUTXの予測収益成長率 (年間6.7% ) は 貯蓄率 ( 3.7% ) を上回っています。

収益対市場: NUTXの収益 ( 6.7% ) US市場 ( 17.1% ) よりも低い成長が予測されています。

高成長収益: NUTXの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: NUTXの収益 ( 8.1% ) US市場 ( 13.3% ) よりも低い成長が予測されています。

高い収益成長: NUTXの収益 ( 8.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NUTXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/15 11:08
終値2026/09/15 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Nutex Health Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Anderson SchockB. Riley Securities, Inc.
Yuan ZhiB. Riley Securities, Inc.
Eugene MannheimerFreedom Capital Markets